News

FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Biosimilars for Treatment of Inflammatory Diseases Across Latin America
Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and ...
Physician's Weekly5h
FDA Approves Dupixent for Bullous Pemphigoid
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...
Nektar's lead drug candidate shows promise in eczema trial, shares soar
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...